Wang X, et al. - In the present study, the researchers sought to evaluate the completion rates, risk factors for non-completion, and cost impact for non-completion in patients receiving capecitabine monotherapy (Cape) or capecitabine with oxaliplatin (CAPOX) for the adjuvant treatment of early-stage colon cancer. between April 2013 and March 2017, patients with a diagnosis of early-stage colon cancer were retrospectively identified. Adverse events, costs, healthcare resource utilization, and cost impact for non-completion have been examined. In total, 673 patients met the eligibility criteria, of which 382 (57%) were treated with Cape and 291 (43%) with CAPOX. Adjuvant capecitabine-based chemotherapy has a low real-world completion rate in patients with early-stage colon cancer. Non-completion of therapy is linked to higher baseline healthcare costs. Non-chemotherapy costs are significantly higher in non-completers than in completers, emphasising the financial burden of managing adverse events and pre-existing comorbidities, which may lead to early therapy discontinuation. Adherence monitoring may be an effective strategy for optimizing the completion of oral chemotherapy.